Ennature Bio Pharma Limited
NSE: ENNATURE · Biotechnology
Share price ₹167.65
down 6.03% · close of 20 Nov 2026
Your ratios
Market cap
₹375 Cr
P/E ratio
261.9
EPS FY to Mar 2026
P/B ratio
—
ROCE
—
ROE
—
Dividend yield
0.0%
as of 19 Nov 2026
1 · Overview
Overview
Price, valuation, sales and profit over the range you pick. Prices as of the last close; results as filed.
At a glance · Max
Every small chart follows the range above. Point at it to read a value; click it to open it.2 · Results
Latest result · Q2 FY27
What the last results showed. Whether management kept its word is in Pro.
Net profit ₹4.89 Cr in the quarter to Sep 2026
Years to March, 2026–2026 · key lines
| Line | Mar 2026FY26 |
|---|---|
| Sales₹ crore | 246 |
| Expenses₹ crore | 217 |
| Operating profit₹ crore | 29 |
| Operating margin% of sales | 12.00% |
| Interest₹ crore | 13 |
| Depreciation₹ crore | 14 |
| Profit before tax₹ crore | 2 |
| Tax rate% of profit before tax | 23.00% |
| Net profit₹ crore | 1 |
| EPS₹ per share | 605.00 |
Small figure: change on the year before. Lines that are 0 or blank in every column are not shown.
The last 3 quarters, Sep 2025 to Sep 2026 · key lines
| Line | Sep 2025Q2 FY26 | Jun 2026Q1 FY27 | Sep 2026Q2 FY27 |
|---|---|---|---|
| Sales₹ crore | 54.14 | 90.39 | 78.46change on a year before +45% |
| Expenses₹ crore | 48.10 | 80.40 | 68.12 |
| Operating profit₹ crore | 6.04 | 9.99 | 10.34change on a year before +71% |
| Operating margin% of sales | 11.16% | 11.05% | 13.18% |
| Interest₹ crore | 3.79 | 0.04 | 0.03 |
| Depreciation₹ crore | 3.61 | 3.70 | 3.70 |
| Profit before tax₹ crore | -1.36 | 6.25 | 6.61 |
| Tax rate% of profit before tax | -5.88% | 25.44% | 26.17% |
| Net profit₹ crore | -1.28 | 4.66 | 4.89 |
| EPS₹ per share | -640.00 | 2,330.00 | 2.19 |
Small figure: change on the same quarter a year earlier. Lines that are 0 or blank in every column are not shown.
3 · Quality & value
Answers
The questions investors ask most, each answered first in one line, then shown. From the company's own numbers.
How fast it has been growing
Fewer than three years of filings — too early to judge growth.
Whether it grew faster than its sector
We do not have three full years of its sales yet, so there is nothing to compare with its sector.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
It has no steady three-year profit record yet, so growth cannot be weighed against the price.
How it compares with its peers
Against companies across the whole Healthcare sector, it ranks 142 of 192 on margin.
A longer bar is a better rank.
What makes it hard to beat — and is that still true?
It is losing money on the capital in the business, so there is no advantage to measure.
Whether its growth pays for itself
Only 0 years of matching accounts on file — too few to judge this yet.
Peers here are the 191 companies across the whole Healthcare sector. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Business score & profit checks
How strong the business is, and whether its profit is real cash. Facts only, not advice.
Business score
19 out of 100
How strong the business is, in one number. Last changed 20 Nov 2026.
Profit checks: is the profit real cash?
Not enough filed accounts to run these checks yet.
Key numbers & peers
Grouped by topic. Each number says what period it is for.
Price
- Market cap
- ₹375 Cr
- Prev close
- ₹167.65
- 52w High
- ₹265
- 52w Low
- ₹165
- Beta
- —
- Price CAGR 1y
- —
- Price CAGR 3y
- —
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Valuation
- P/E ratioEPS FY to Mar 2026
- 261.9
- Industry P/E
- 37.0
- P/B ratio
- —
- EV / EBITDA
- —
- Enterprise value
- —
- PEG ratio
- —
- Dividend yield
- 0.0%
Returns
- ROCE
- —
- ROCE 5y average
- —
- ROE
- —
- ROE 3y average
- —
- ROE last year
- —
- Return on assets
- —
Sales, profit & margins
- Annual revenue
- ₹246 Cr
- Annual profit
- ₹1.00 Cr
- EPS
- ₹605
- Operating margin
- 12.0%
- Net profit margin
- 0.4%
- EBITDA margin
- 11.8%
- Sales latest quarterSep 2026 quarter
- ₹78.5 Cr
- Profit latest quarterSep 2026 quarter
- ₹4.89 Cr
- OPM latest quarterSep 2026 quarter
- 13.2%
Growth a year
- Sales growth 3y
- —
- Sales growth 5y
- —
- Sales growth TTM
- —
- Profit growth 3y
- —
- Profit growth 5y
- —
- Profit growth TTM
- —
- YoY quarterly sales growthSep 2026 vs Sep 2025
- 44.9%
- YoY quarterly profit growth
- —
Balance sheet
- Book Value
- ₹238
- Face Value
- ₹5.0
- Borrowings
- —
- Total debt
- ₹0.00 Cr
- Total cash
- ₹0.00 Cr
- Debt / Equity
- 0.0
- Interest coverage
- 1.2
- Reserves / Equity
- —
Cash & payout
- Operating cash flow
- —
- Free cash flow
- —
- FCF yield
- —
- Net cash flow
- —
- Dividend payout
- 0.0%
Holdings
- Promoter holding
- 59.6%
- FII holding
- 2.4%
- DII holding
- 4.6%
- Public holding
- 33.3%
Peers
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield | Profit qtr ₹ Cr | Profit change | Sales qtr ₹ Cr | Sales change | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 1,884.90 | 36.8 | 4,52,244 | 0.86% | 1,995 | -36.16% | 16,199 | +11.88% | 20.60% |
| Divi's Laboratories | 11,180.50 | 86.7 | 2,96,283 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharmaceuticals | 4,689.50 | 81.1 | 1,78,370 | 0.82% | 534 | -9.64% | 4,979 | +50.79% | 19.56% |
| Laurus Labs Limited | 2,294.60 | 92.5 | 1,23,977 | 0.09% | 436 | +124.84% | 2,206 | +33.44% | 17.97% |
| Anthem Biosciences Limited | 951.05 | 84.9 | 53,595 | 0.21% | 211 | +22.23% | 594 | +8.00% | 30.45% |
| Advanced Enzyme Technologies Limited | 290.45 | 19.7 | 3,203 | 1.84% | 51.0 | +13.33% | 215 | +16.51% | 14.45% |
| Ennature Bio Pharma Limited | 167.65 | 261.9 | 375 | 0.00% | 4.89 | 78.5 | +44.92% | ||
| Vivo Bio Tech Limited | 16.01 | 35.5 | 0.00% | 1.10 | +26.68% | 17.2 | +31.13% | 7.70% | |
| Medianof the whole group of 133, 20 Nov 2026 | 35.2 | 0.09% | +30.69% | +19.60% | 14.96% |
Median: the middle value of the whole peer group of 133 companies. Price and rupee sizes are left blank there, as a middle value of those says little.
Competes with 7 listed companies
Advanced Enzyme Technologies Limited, Anthem Biosciences Limited, Divi's Laboratories, Laurus Labs Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Vivo Bio Tech Limited
4 · Balance sheet & cash
Balance sheet
What the company owns and what it owes, at each year end and at the filed half-years. ₹ crore.
This company does not publish this table.
Cash flows
Real money coming in and going out — from the business, from investments and from loans. ₹ crore.
This company does not publish this table.
Efficiency ratios
How fast customers pay and how well capital earns.
This company does not publish this table.
5 · Owners & payouts
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
No dividends, splits or big trades on record.
6 · Price & trading
Open interestPRO
Where option traders are positioned on this stock.
7 · Business
About
What the company is, from our own records: where it sits, where its revenue comes from, and where it works.
- Sector
- Healthcare
- Industry
- Biotechnology
- Symbol
- ENNATURE
- ISIN
- INE2WCT01016
Sites · 2
- Dehradun facilityDehradun, Uttarakhand
- Kashipur facilityKashipur, Uttarakhand
Industry numbers
The numbers that matter most in this industry, from the company's own filings and earnings calls. Each one says its period.
Revenue and margin
- EBIT marginSep 2026 quarter8.46%
Profit quality
- Other income shareSep 2026 quarter0.00%
- Interest coverSep 2026 quarter265.46x
Growth
- Revenue growth (YoY)Sep 2026 quarter44.92%
How they have moved
EBIT margin · quarterly
Source: Computed from the filings
| Sep 26 | 8.46% | Computed from the filings |
| Jun 26 | 6.96% | Computed from the filings |
| Mar 26 | — | not filed |
| Dec 25 | — | not filed |
| Sep 25 | 4.49% | Computed from the filings |
Other income share · quarterly
Source: Computed from the filings
| Sep 26 | 0.00% | Computed from the filings |
| Jun 26 | 0.00% | Computed from the filings |
Interest cover · quarterly
Source: Computed from the filings
| Sep 26 | 265.46x | Computed from the filings |
| Jun 26 | 157.25x | Computed from the filings |
| Mar 26 | — | not filed |
| Dec 25 | — | not filed |
| Sep 25 | 0.64x | Computed from the filings |
Supply chain
Links to other companies, as recorded in our map from filings and announcements. A news event that hits one of them can reach Ennature Bio Pharma Limited through this map.
Uses as raw material · 5
- Centella asiatica leaves
- Gloriosa superba seedFrom India
- Guar beans
- Nicotiana tabacum leaf
- Voacanga africana seeds
Depends on the price of · 4
- Medicinal HerbsA higher price hurts it
- Tobacco LeafA higher price hurts it
- fuelA higher price hurts it
- sugarcaneA higher price hurts it
Competes with · 7 companies
- Sun Pharmaceutical
- Divi's Laboratories
- Torrent Pharmaceuticals
- Laurus Labs
- Anthem Biosciences
- Advanced Enzyme Technologies
- Vivo Bio Tech
Shaded: the companies compared in Key numbers & peers. Each name opens that company’s page.
8 · News & documents
News and what it reaches
Filings and news about Ennature Bio Pharma Limited, and bigger events that reach it through its owners, rivals, customers or suppliers. Newest first. Open one to see how the effect spreads.
No recent news or filings for this company.
Documents
Earnings calls, results presentations and annual reports, straight from the company and the exchanges.
No documents on record yet.
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.